Letters to the editor that in rapid-cycling discontinuation subjects (0.82). The authors do not tell the readers whether this post hoc comparison is statistically significant, but I highly doubt that it is, considering the paltry sample sizes of the 2 groups (7 who continued antidepressants vs 10 who discontinued). Furthermore, among non-rapid cycling patients, the continuation of antidepressants appeared to be associated with an almost halving of the number of depressive episodes per year vis à vis discontinuation of antidepressants (0.42 vs 0.70).
All of these data simply make no sense: why would antidepressant continuation be protective in non-rapid cycling subjects but "depressogenic" in rapid cycling subjects? Furthermore, why would this presumed enhancement of mood episode recurrences be true only for depressions and not for manias, the latter being the heretofore feared event among the bipolar mavens who are largely against such compounds?
Finally, the sample sizes in the group in question, namely rapid-cycling subjects, are so small (7 and 10), that this trial hardly qualifies as a randomized controlled trial for them-at best, it is a very preliminary pilot project, the conclusions of which have been misleadingly stated in the abstract. In fact, I suspect the results in rapid-cycling patients were influenced by 1 or 2 outliers, and I challenge the authors to present data for each of these patients.
In my opinion, the readers of the Journal of Clinical Psychiatry were not well served by this cynically spun article.
